scholarly journals Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

2016 ◽  
Vol 7 (4) ◽  
pp. 565-573 ◽  
Author(s):  
Yutaka Seino ◽  
Shizuka Kaneko ◽  
Shuichi Fukuda ◽  
Takeshi Osonoi ◽  
Toshihiko Shiraiwa ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Combination Therapy ◽  
Japanese Patients ◽  
Double Blind ◽  
Parallel Group ◽  
Parallel Group Trial ◽  
Group Trial

scholarly journals Starting triple oral hypoglycemic agent therapy in poorly controlled type 2 diabetes is a suitable therapeutic strategy to lower HbA1c when insulin therapy is not desired

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Mara A Darian
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Therapy ◽  
Therapeutic Strategy ◽  
Clinical Decision ◽  
Double Blind ◽  
Hypoglycemic Agent ◽  
Parallel Group ◽  
Parallel Group Trial ◽  
Group Trial

A clinical decision report using: Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care. 2016;40(2):201-209. https://doi.org/10.2337/dc16-1347 for a patient with uncontrolled type 2 diabetes on metformin and sitagliptin and hesitant to begin insulin therapy.

scholarly journals Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

Diabetes Care ◽  
2016 ◽  
Vol 40 (2) ◽  
pp. 201-209 ◽  
Author(s):  
Eirik Søfteland ◽  
Juris J. Meier ◽  
Bente Vangen ◽  
Robert Toorawa ◽  
Mario Maldonado-Lutomirsky ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Double Blind ◽  
Parallel Group ◽  
Parallel Group Trial ◽  
Group Trial
Sign in / Sign up

Export Citation Format

Share Document